Longevity Health Holdings Reports Improved Financial Performance and Strategic Acquisition

Longevity Health Holdings, Inc. (formerly Carmell Corporation) reported a significant financial performance for the fiscal year ending December 31, 2024, with a net loss of $10.7 million, a 34% improvement from the previous year's loss of $16.2 million. The company generated gross sales of $90,829 from its newly launched cosmetic skincare products, resulting in net sales of $50,318 after discounts. This marks a notable shift as the company transitions from its previous focus on bone and tissue healing products to a more consumer-oriented skincare line. The total operating expenses decreased by 15% to $5.04 million, primarily due to reduced research and development costs as the company halted clinical studies on longer-term projects.

In a strategic move, Longevity Health completed the acquisition of Elevai Labs on January 16, 2025, for approximately $1.08 million, which included both cash and stock. The Elevai product line, which generated $2.5 million in sales for the year 2024, is expected to enhance the company's revenue stream as it integrates these assets into its existing portfolio. Additionally, the company raised $1.85 million through a private placement of shares and warrants in January 2025, which is intended to bolster its liquidity and support ongoing operations.

Operationally, the company has made significant changes, including a reduction in employee headcount to 15 as of March 27, 2025, and a strategic refocus on its cosmetic product lines. The company has also experienced a shift in its market approach, emphasizing direct-to-consumer sales alongside traditional business-to-business channels. This pivot is expected to enhance customer engagement and broaden market reach, particularly in the growing aesthetics market, which is projected to expand at a compound annual growth rate of 6.4% through 2028.

Despite these developments, the company faces challenges, including a substantial doubt about its ability to continue as a going concern due to negative working capital of $4.9 million and ongoing operational losses. Management has indicated the need for additional capital to sustain operations and is exploring various financing options, including potential out-licensing of research programs. The company is also navigating compliance issues with Nasdaq, having received notifications regarding its market value and stock price, which could impact its listing status.

Looking ahead, Longevity Health Holdings aims to leverage its recent acquisitions and product launches to drive revenue growth while managing costs effectively. The company plans to continue its focus on the cosmetic skincare market, with additional product launches anticipated in 2025, including new offerings under the Elevai brand. However, the success of these initiatives will depend on market acceptance and the company's ability to maintain compliance with regulatory and listing requirements.